Histogenics Corporation to Present at Upcoming Investor Conferences
February 20 2018 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in
the development of restorative cell therapies that may offer
rapid-onset pain relief and restored function, announced that
Company Management will be presenting at two upcoming healthcare
investor conferences.
- Canaccord Genuity 2018 Musculoskeletal
Conference – New Orleans (March 6,
2018)Adam Gridley, Histogenics’ CEO, will present a
corporate overview on Tuesday, March 6, 2018 at 8:00 a.m. CT / 9:00
a.m. ET. The conference immediately precedes the American
Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores
the current state of orthopedics, biologics, imaging, robotic
surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 38th Annual Health Care Conference –
Boston, MA (March 12-14, 2018)Mr. Gridley will present a
corporate overview on Wednesday, March 14, 2018 at 8:40 a.m.
ET.
To access a live audio webcast of the presentations on the
“Investor Relations” page of the Histogenics website, please click
here. The webcasts will be available for approximately 45
days following the respective conferences.
About Histogenics
Corporation
Histogenics (Nasdaq:HSGX) is a leader in the
development of restorative cell therapies that may offer
rapid-onset pain relief and restored function. Histogenics’
lead investigational product, NeoCart®, is designed to rebuild a
patient’s own knee cartilage to treat pain at the source and may
prevent a patient’s progression to osteoarthritis. NeoCart is
one of the most rigorously studied restorative cell therapies for
orthopedic use. Histogenics recently completed enrollment of
its NeoCart Phase 3 clinical trial and expects to report top-line,
one-year superiority data in the third quarter of 2018.
NeoCart is designed to perform like articular hyaline cartilage at
the time of treatment, and as a result, may provide patients with
more rapid pain relief and accelerated recovery as compared to the
current standard of care. Histogenics’ technology platform has the
potential to be used for a broad range of additional restorative
cell therapy indications. For more information on Histogenics
and NeoCart, please visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Sep 2023 to Sep 2024